293 related articles for article (PubMed ID: 30132029)
1. The bark giving diabetes therapy some bite: the SGLT inhibitors.
Marshall SM
Diabetologia; 2018 Oct; 61(10):2075-2078. PubMed ID: 30132029
[No Abstract] [Full Text] [Related]
2. Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?
Pitt B; Bhatt DL
Circulation; 2021 Jul; 144(1):4-6. PubMed ID: 33887961
[No Abstract] [Full Text] [Related]
3. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
Kumar S; Khatik GL; Mittal A
Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
[TBL] [Abstract][Full Text] [Related]
4. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
5. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
Peacock SC; Lovshin JA; Cherney DZI
Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
[No Abstract] [Full Text] [Related]
7. Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts.
Sánchez-Muñoz E; Requena-Ibáñez JA; Badimón JJ
Rev Esp Cardiol (Engl Ed); 2024 Jul; 77(7):510-514. PubMed ID: 38521442
[No Abstract] [Full Text] [Related]
8. SGLT2 inhibitors race to enter type-2 diabetes market.
Sheridan C
Nat Biotechnol; 2012 Oct; 30(10):899-900. PubMed ID: 23051788
[No Abstract] [Full Text] [Related]
9. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Wan HX; Shen JK
Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
[TBL] [Abstract][Full Text] [Related]
10. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials.
Adeghate E; Mohsin S; Adi F; Ahmed F; Yahya A; Kalász H; Tekes K; Adeghate EA
Expert Opin Investig Drugs; 2019 Sep; 28(9):811-820. PubMed ID: 31402716
[No Abstract] [Full Text] [Related]
11. Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.
Alvarez CA; Neeland IJ; McGuire DK
Diab Vasc Dis Res; 2015 Mar; 12(2):74-7. PubMed ID: 25690133
[No Abstract] [Full Text] [Related]
12. Bioanalytical methods for quantification of novel sodium-glucose cotransporter 2 inhibitors: toward greener approach in separation science.
Shrivastav PS; Shah PA; Nambiar AP; George A; Sharma V; Sharma P
Bioanalysis; 2020 May; 12(9):565-568. PubMed ID: 32412301
[No Abstract] [Full Text] [Related]
13. The Na
Koepsell H
Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
[TBL] [Abstract][Full Text] [Related]
14. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
15. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Ghezzi C; Loo DDF; Wright EM
Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032
[TBL] [Abstract][Full Text] [Related]
16. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Wang YJ; Hao CM
Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
[TBL] [Abstract][Full Text] [Related]
17. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors.
Xu G; Gaul MD; Kuo GH; Du F; Xu JZ; Wallace N; Hinke S; Kirchner T; Silva J; Huebert ND; Lee S; Murray W; Liang Y; Demarest K
Bioorg Med Chem Lett; 2018 Nov; 28(21):3446-3453. PubMed ID: 30268701
[TBL] [Abstract][Full Text] [Related]
19. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
20. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
